Potentiation of Simian Immunodeficiency Virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen

Journal of Immunology

Volumn 167, Issue 12, 2001, Pages 7180-7191

  Hel, Z ^a   Tsai, W P ^a   Thornton, A ^a   Nacsa, J ^a   Giuliani, L ^a   Tryniszewska, E ^a   Poudyal, M ^a   Venzon, D ^a   Wang, X ^a   Altman, J ^a   Watkins, D I ^a   Lu, W ^a   Von Gegerfelt, A ^a   Felber, B K ^a   Tartaglia, J ^a   Pavlakis, G N ^a   Franchini, G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAG PROTEIN; GENE PRODUCT; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; TREATMENT PLANNING; VACCINATION; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0035892889     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.12.7180     Document Type: Article

References (71)

1. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
2. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
3. + T cell depletion in simian immunodeficiency virus-infected macaques
4. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
5. + T-cell responses associated with control of viremia
6. + lymphocytes
7. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
8. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
9. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
10. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo
11. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
12. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
13. Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques
14. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type I syndrome
15. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
16. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
17. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
18. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells
19. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type I infection
20. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
21. 251 infection of macaques
22. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
23. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection
24. Immune control of HIV-1 after early treatment of acute infection
25. mac251: Dependence on route of challenge exposure
26. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
27. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
28. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
29. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
30. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques
31. mac251-infected macaques previously immunized with NYVAC-SIV vaccines
32. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques
33. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
34. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases
35. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver
36. + T cell responses induced by recombinant influenza and vaccinia viruses
37. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases
38. Poxvirus-based vectors as vaccine candidates
39. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
40. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
41. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
42. DNA vaccines: A key for inducing long-term cellular immunity
43. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization
44. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
45. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV
46. Simian immunodeficiency virus DNA vaccine trial in macaques
47. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys
48. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
49. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
50. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
51. An improved plasmid DNA expression vector for direct injection into skeletal muscle
52. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses
53. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation
54. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression
55. mac239 generated a Rev-independent infectious virus able to propagate in rhesus peripheral blood mononuclear cells
56. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent
57. - human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes
58. *01 in the rhesus macaque detected by PCRSSP and direct sequencing
59. Phenotypic analysis of antigen-specific T lymphocytes
60. Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: Evidence of minimal genetic drift and low pathogenic effects
61. *01: Implications for vaccine design and testing
62. *01) that binds an immunodominant CTL epitope from simian immunodeficiency virus
63. mac-infected rhesus monkeys
64. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
65. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
66. Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys
67. Different Th cell types and antibody isotypes generated by saline and gene gun DNA immunization
68. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion
69. + T cells
70. mac-induced immunodeficiency
71. KU2-infected macaques